Clinical Trials Details

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

IRB Protocol Number

AFT-65/GS-US-595-6184

Clinical Trial Categories

• Breast Cancer

How to Participate

Eligibility:

Men or women ages 18 and older, with history of triple negative breast cancer (ER negative, PR negative, HER2 negative) clinical stage T1, N1-2 or T2-4, N0-2, who have been found to have residual disease in breast or lymph node(s) after completion of neoadjuvant therapy and surgery. The presence of distant metastatic disease must be ruled out.